IRVINE, CA / ACCESSWIRE / March 17, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against AmTrust Financial Services Inc. (“AmTrust” or the “Company”) (NASDAQ: AFSI). Investors, who purchased or otherwise acquired AmTrust shares between May 10, 2016, and February 24, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the May 1, 2017 lead plaintiff deadline.

If you purchased shares of AmTrust during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

On February 27, 2017, AmTrust stated that it “identified material weaknesses in its internal control over financial reporting that existed as of December 31, 2016, specifically related to ineffective assessment of the risks associated with the financial reporting, and an insufficient complement of corporate accounting and corporate financial reporting resources within the organization.” AmTrust will stall filing its 2016 financial statements.

When this information was announced to the investing public, AmTrust stock dropped, causing investors harm.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 457582

IRVINE, CA / ACCESSWIRE / March 17, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Invuity, Inc. (“Invuity” or the “Company”) (NASDAQ: IVTY). Investors, who purchased or otherwise acquired Invuity shares between July 19, 2016, and November 3, 2016, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 28, 2017 lead plaintiff deadline.

If you purchased shares of Invuity during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

On November 3, 2016, Invuity announced its financial results for the third quarter of 2016 and, recognizing in part a decrease in average revenue per account, the Company lowered its guidance.

When this information was announced to the investing public, Invuity stock dropped, causing investors harm.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 457583

IRVINE, CA / ACCESSWIRE / March 17, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Aetna Inc. (“Aetna” or the “Company”) (NYSE: AET) concerning possible violations of federal securities laws. Investors, who purchased or otherwise acquired shares between August 15, 2016 and January 20, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 27, 2017 lead plaintiff motion deadline.

If you purchased shares of Aetna. during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

The Complaint alleges that during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: Aetna and its senior executives attempted to sway Aetna’s engagement in the Public Exchanges for positive treatment from regulators in regards to the Humana acquisition; that the Company threatened to rescind its participation in public health insurance exchanges if the Department of Justice (“DOJ”) attempted to block the merger; that Aetna withdraw from some public health insurance exchanges, as per its threat of leaving the marketplace once the DOJ filed suit to improve its litigation; that Aetna withdrew from public health insurance exchanges that were profitable for Aetna; and that as a result, Defendants’ statements regarding Aetna’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis. When this information was revealed to the investing public, the value of Aetna fell, causing investors serious harm.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 457576

IRVINE, CA / ACCESSWIRE / March 17, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against USANA Health Sciences, Inc. (“USANA” or the “Company”) (NYSE: USNA) concerning possible violations of federal securities laws. Investors, who purchased or otherwise acquired shares between March 14, 2014 and February 7, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the April 14, 2017 lead plaintiff motion deadline.

If you purchased shares of USANA during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

USANA develops, manufactures, and sells nutritional and personal care products primarily to reduce the risk of chronic degenerative disease.

On February 7, 2017, USANA revealed that it will be starting an internal investigation of its Chinese subsidiary, BabyCare Ltd. (“BabyCare”).

In particular, the Company’s investigation concerns “compliance with the Foreign Corrupt Practices Act,” as well as “BabyCare’s expense reimbursement policies.”

When this information was revealed to the investing public, the value of USANA declined, causing investors serious harm.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 457579

NEW YORK, NY / ACCESSWIRE / March 17, 2017 / Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a clinical stage biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage, and infection, will be presenting at this year’s The MicroCap Conference on April 4th in New York City, sponsored by The Special Equities Group and Maxim Group. David C. Cavalier, Chairman and Chief Financial Officer, will be giving the presentation and meeting with investors.

Mr. Cavalier will provide an update on Aeolus’ development pipeline, including its $118.4 million advanced R & D contract with the Biomedical Advanced Research and Development Authority (“BARDA”), a division of the U.S. Department of Health and Human Services. The BARDA contract funds the advanced development of AEOL 10150 (“10150”) for the treatment of the pulmonary and delayed effects of acute radiation exposure (“Lung-ARS”) following a nuclear detonation or accident. 10150 has demonstrated efficacy in multiple mouse and non-human primate Lung-ARS studies, and is being developed under the FDA Animal Rule, which allows the use of animal studies in indications where human efficacy trials are not possible. 10150 is also being developed for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) and for use in oncology to reduce the side effects of radiation therapy for solid tumors. The Company is also developing AEOL 11114 as a treatment for Parkinson’s disease with support from the Michael J. Fox Foundation for Parkinson’s disease. A third compound, AEOL 20415, is in development for the treatment of infectious diseases.

CONFERENCE OVERVIEW AND STRUCTURE

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors.

The MicroCap Conference will take place in New York City at the Essex House on April 4th. Registration will begin on Tuesday, April 4th, at 7:00AM, and will last until the evening. These days will be jam-packed with company sessions, presentations, good food, and plenty of time to network with other investors over drinks at the reception. This event does not allow service providers – only portfolio managers, analysts, and private investors.

REGISTRATION FOR INVESTORS

To register, please go to our website (www.microcapconf.com) and click “Register.”

PARTICIPATING COMPANIES

For our most updated list of companies, please go to our website (http://microcapconf.com/conferences/new-york-2017/).

MARQUEE SPONSORS

The Special Equities Group
Maxim Group

PARTICIPATING SPONSORS

MZ Group
Core IR
Marcum
PCG Advisory Group

News Compliments of ACCESSWIRE.

FOR MORE INFORMATION

Please visit: www.microcapconf.com

Or, contact Tony Yu at tony@microcapconf.com.

SOURCE: Aeolus Pharmaceuticals, Inc.

ReleaseID: 457581

NEW YORK, NY / ACCESSWIRE / March 17, 2017 / Levi & Korsinsky announces it has commenced an investigation of Cogent Communications Holdings, Inc. (NASDAQ: CCOI) concerning possible breaches of fiduciary duty. To obtain additional information, go to:

http://zlk.9nl.com/cogent-communications-ccoi

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 457588

NEW YORK, NY / ACCESSWIRE / March 17, 2017 / Aspen Group, Inc. (OTCQB: ASPU) will be presenting at this year’s The MicroCap Conference on April 4th in New York City, sponsored by The Special Equities Group and Maxim Group.

CONFERENCE OVERVIEW AND STRUCTURE

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors.

The MicroCap Conference will take place in New York City at the Essex House on April 4th. Registration will begin on Tuesday, April 4th, at 7:00AM, and will last until the evening. These days will be jam-packed with company sessions, presentations, good food, and plenty of time to network with other investors over drinks at the reception. This event does not allow service providers – only portfolio managers, analysts, and private investors.

REGISTRATION FOR INVESTORS

To register, please go to our website (www.microcapconf.com) and click “Register.”

PARTICIPATING COMPANIES

For our most updated list of companies, please go to our website (http://microcapconf.com/conferences/new-york-2017/).

MARQUEE SPONSORS

The Special Equities Group
Maxim Group

PARTICIPATING SPONSORS

MZ Group
Core IR
Marcum
PCG Advisory Group

News Compliments of ACCESSWIRE.

FOR MORE INFORMATION

Please visit: www.microcapconf.com

Or, contact Tony Yu at tony@microcapconf.com.

SOURCE: Aspen Group, Inc.

ReleaseID: 457578

LOS ANGELES, CA / ACCESSWIRE / March 17, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (NASDAQ: STML) concerning possible violations of federal securities laws. Investors, who purchased or otherwise acquired Stemline shares between January 19, 2017 and February 1, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 4, 2017 lead plaintiff deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

On February 2, 2017, Bloomberg confirmed that a patient undergoing a clinical trial of Stemline’s cancer drug SL-401 died from a severe side effect, the third death related to SL-401 toxicity.

When this information was revealed to the public, the value of Stemline stock fell sharply, causing investors serious harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 457573

NEW YORK, NY / ACCESSWIRE / March 17, 2017 / Legacy Education Alliance Inc. (OTCQB: LEAI) Chief Financial Officer, Christian A. J. Baeza, will be the featured presenter at the MicroCap Conference on April 4th in New York City, sponsored by The Special Equities Group and Maxim Group. Mr. Baeza will be available for one-on-one investor meetings throughout the conference.

CONFERENCE OVERVIEW AND STRUCTURE

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other investors.

The MicroCap Conference will take place in New York City at the Essex House on April 4th. Registration will begin on Tuesday, April 4th, at 7:00AM, and the event ends with a reception in the evening. The day will be jam-packed with company presentations, one-on-one meetings, good food, and plenty of time to network with other investors over drinks at the reception. This event does not allow service providers – only portfolio managers, analysts, and private investors.

REGISTRATION FOR INVESTORS

To register, please go to our website (www.microcapconf.com) and click “Register.”

PARTICIPATING COMPANIES

For our most updated list of companies, please go to our website (http://microcapconf.com/conferences/new-york-2017/).

MARQUEE SPONSORS

The Special Equities Group
Maxim Group

PARTICIPATING SPONSORS

MZ Group
Core IR
Marcum
PCG Advisory Group

News Compliments of ACCESSWIRE.

About Legacy Education Alliance Inc.

Legacy Education Alliance, Inc. (http://www.legacyeducationalliance.com) is a leading international provider of practical, high-quality, and value-based educational training on the topics of personal finance, entrepreneurship, real estate, and financial markets investing strategies and techniques. Legacy Education Alliance was founded in 1996. Today, we are a global company with approximately 200 employees that has cumulatively served more than two million students from more than 150 countries and territories over the course of our operating history.

We offer our training through a variety of brands, including Rich Dad® Education, Rich Dad® Stock Education, Making Money from Property with Martin RobertsTM, Brick Buy BrickTM, Building Wealth, Robbie Fowler Property AcademyTM, Women in WealthTM, The Independent WomanTM, Trade Up Investor EducationTM, and Elite Business StarTM. For more information, visit our website at www.legacyeducationalliance.com.

FOR MORE INFORMATION ON THE MICROCAP CONFERENCE:

Please visit: www.microcapconf.com

Or, contact Tony Yu at tony@microcapconf.com.

Investor Contact

CORE IR
Scott Gordon
516 222 2560
scottg@coreir.com

SOURCE: Legacy Education Alliance Inc.

ReleaseID: 457577